Cytosorbents (CTSO) Resumen de Acciones
Cytosorbents Corporation se dedica a la investigación, desarrollo y comercialización de dispositivos médicos con su plataforma tecnológica de purificación de la sangre en Estados Unidos, Alemania y a escala internacional. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 3/6 |
| Crecimiento futuro | 3/6 |
| Rendimiento pasado | 0/6 |
| Salud financiera | 1/6 |
| Dividendos | 0/6 |
Recompensas
Análisis de riesgos
CTSO Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Competidores de Cytosorbents Corporation
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | US$0.36 |
| Máximo en las últimas 52 semanas | US$1.22 |
| Mínimo de 52 semanas | US$0.35 |
| Beta | 1.39 |
| Cambio en 1 mes | -24.53% |
| Variación en 3 meses | -45.45% |
| Cambio de 1 año | -65.05% |
| Variación en 3 años | -90.39% |
| Variación en 5 años | -95.17% |
| Variación desde la OPV | -99.18% |
Noticias y actualizaciones recientes
CTSO: Nasdaq Extension And Clinical Data Will Support Future Upside Potential
Analysts have reduced their fair value estimate for Cytosorbents from $10.00 to $5.00, citing updated assumptions that now reflect a higher discount rate, more moderate revenue growth expectations, slightly lower profit margin forecasts, and a modestly lower future P/E multiple. What's in the News Nasdaq granted Cytosorbents a 180 day extension, until September 28, 2026, to regain compliance with the minimum US$1.00 bid price requirement for continued listing under Nasdaq Listing Rule 5550(a)(2).
CTSO: Nasdaq Compliance Extension Will Support Future Turnaround Potential
Analysts have reduced their fair value estimate for Cytosorbents from $5.00 to $2.88 as they recalibrate assumptions for revenue growth, profit margins, the discount rate, and the stock's future P/E multiple. What's in the News On April 1, 2026, Cytosorbents received a 180 day extension from Nasdaq until September 28, 2026 to regain compliance with the minimum US$1.00 bid price requirement for continued listing.Recent updates
CTSO: Nasdaq Extension And Clinical Data Will Support Future Upside Potential
Analysts have reduced their fair value estimate for Cytosorbents from $10.00 to $5.00, citing updated assumptions that now reflect a higher discount rate, more moderate revenue growth expectations, slightly lower profit margin forecasts, and a modestly lower future P/E multiple. What's in the News Nasdaq granted Cytosorbents a 180 day extension, until September 28, 2026, to regain compliance with the minimum US$1.00 bid price requirement for continued listing under Nasdaq Listing Rule 5550(a)(2).CTSO: Nasdaq Compliance Extension Will Support Future Turnaround Potential
Analysts have reduced their fair value estimate for Cytosorbents from $5.00 to $2.88 as they recalibrate assumptions for revenue growth, profit margins, the discount rate, and the stock's future P/E multiple. What's in the News On April 1, 2026, Cytosorbents received a 180 day extension from Nasdaq until September 28, 2026 to regain compliance with the minimum US$1.00 bid price requirement for continued listing.
CTSO: ICU Utilization And Nasdaq Compliance Extension Will Support Future Upside
Analysts have kept the fair value estimate for Cytosorbents steady at $0.75. Modest tweaks to assumptions for the discount rate, revenue growth, profit margin, and future P/E reflect updated views on risk, earnings power, and likely valuation multiples.CTSO: ICU Adoption And Nasdaq Compliance Efforts Will Support Future Upside
Analysts have maintained their $0.75 price target on Cytosorbents. They cite small adjustments in the discount rate, revenue growth assumptions, and future P/E estimates as they refine their models, while keeping their overall valuation view unchanged.CTSO: 2025 Revenue Outlook And ICU Adoption Will Support Upside
Analysts have maintained their $0.75 price target for Cytosorbents, citing only modest adjustments to assumptions for discount rate, revenue growth, profit margin, and future P/E that do not materially change their overall view of the stock’s valuation. What's in the News Nasdaq granted CytoSorbents a 180 day extension, until September 28, 2026, to regain compliance with the US$1.00 minimum bid price requirement for continued listing on the exchange, with the stock remaining listed during this period (Delistings notice).CTSO: Steady 2025 Outlook And ICU Therapy Progress Will Support Upside
Analysts have held their fair value estimate for Cytosorbents steady, keeping the implied price target unchanged at $0.75. This reflects slightly adjusted views on discount rate, revenue growth and profit margin assumptions, without a clear shift in overall conviction.CTSO: Steady 2025 Revenue Guidance Will Support Measured Long Term Upside
Analysts have made a modest adjustment to their Cytosorbents price target, citing updated assumptions for discount rate, revenue growth, profit margin, and future P/E. Taken together, these changes leave their fair value estimate broadly unchanged around $0.75.CTSO: Flat 2025 Outlook And Cost Discipline Will Support Measured Upside
Analysts have slightly adjusted their price target for Cytosorbents to reflect updated assumptions around revenue growth, profit margin and future P/E, while keeping the fair value broadly in line at $0.75. What's in the News Cytosorbents issued earnings guidance for the fourth quarter of 2025, with revenue expected to be approximately US$9.2 million, the same figure as guidance for the fourth quarter of 2024 (Key Developments).CTSO: Cost Cuts And 2026 Cash Flow Break Even Will Support Upside
Analysts have trimmed their price target on Cytosorbents to reflect a slightly lower assumed discount rate, marginally higher projected revenue growth, improved profit margin expectations, and a modestly lower future P/E multiple. This results in a revised valuation that they see as better aligned with updated assumptions.CTSO: Cost Cuts And 2026 Cash Flow Break Even Will Shape Outlook
Narrative Update on Cytosorbents Analysts have kept their price target for Cytosorbents steady at US$0.75, citing updated assumptions that reflect slightly lower discount rates, modestly higher projected revenue growth, a stable profit margin outlook, and a small adjustment to expected future P/E levels. What's in the News Cytosorbents issued earnings guidance for the fourth quarter of 2025, with revenue expected to be approximately US$9.2 million, in line with the fourth quarter of 2024 at US$9.2 million (Key Developments).CTSO: Cost Reductions And 2026 Cash Flow Break Even Will Support Upside
Analysts have updated their price target on Cytosorbents and maintained fair value at US$0.75. They have also fine tuned underlying assumptions such as the discount rate, revenue growth, profit margin and future P/E to reflect revised views on the company’s risk and earnings profile.CTSO: Cost Cuts And Nasdaq Listing Risk Will Shape Balanced Outlook
Analysts modestly raised their price target on Cytosorbents to reflect a slightly lower discount rate and higher expected future earnings multiples, even as they tempered long term revenue growth assumptions. What's in the News Cytosorbents announced a strategic workforce and cost reduction plan, cutting approximately 10% of its staff and realigning production and operating expenses to target operating cash flow break even by the first quarter of 2026 (Key Developments).CTSO: Workforce Cuts And FDA Pathway Are Expected To Shape Outlook
Analysts have trimmed their price target on Cytosorbents from approximately 12.84 dollars to 7.96 dollars. This reflects slightly lower long term revenue growth assumptions, a higher perceived risk profile, and only modestly improved profitability expectations.Market Cool On Cytosorbents Corporation's (NASDAQ:CTSO) Revenues Pushing Shares 31% Lower
To the annoyance of some shareholders, Cytosorbents Corporation ( NASDAQ:CTSO ) shares are down a considerable 31% in...Is Cytosorbents (NASDAQ:CTSO) Using Too Much Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...FDA And Health Canada Approval Will Spur ICU Solutions
Cytosorbents’ consensus price target has been raised from $5.00 to $7.00, reflecting improved profitability with net profit margin rising to 12.34% and a more attractive future P/E of 74.11x. What's in the News New studies demonstrate early and intensive CytoSorb® therapy significantly improves clinical outcomes for sepsis and septic shock patients, with peer-reviewed data showing increased survival rates when used intensively and early.Does Cytosorbents (NASDAQ:CTSO) Have A Healthy Balance Sheet?
NasdaqCM:CTSO 1 Year Share Price vs Fair Value Explore Cytosorbents's Fair Values from the Community and select yours...Further Upside For Cytosorbents Corporation (NASDAQ:CTSO) Shares Could Introduce Price Risks After 54% Bounce
Cytosorbents Corporation ( NASDAQ:CTSO ) shareholders would be excited to see that the share price has had a great...
FDA And Health Canada Decisions Will Advance DrugSorb-ATR Launch
Regulatory decisions on DrugSorb-ATR could drive significant revenue growth, especially in the U.S. and Canada, with a large market opportunity.Further Upside For Cytosorbents Corporation (NASDAQ:CTSO) Shares Could Introduce Price Risks After 28% Bounce
Cytosorbents Corporation ( NASDAQ:CTSO ) shareholders are no doubt pleased to see that the share price has bounced 28...The Market Lifts Cytosorbents Corporation (NASDAQ:CTSO) Shares 43% But It Can Do More
Despite an already strong run, Cytosorbents Corporation ( NASDAQ:CTSO ) shares have been powering on, with a gain of...Investors Continue Waiting On Sidelines For Cytosorbents Corporation (NASDAQ:CTSO)
With a price-to-sales (or "P/S") ratio of 1.3x Cytosorbents Corporation ( NASDAQ:CTSO ) may be sending bullish signals...Health Check: How Prudently Does Cytosorbents (NASDAQ:CTSO) Use Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Take Care Before Jumping Onto Cytosorbents Corporation (NASDAQ:CTSO) Even Though It's 28% Cheaper
Unfortunately for some shareholders, the Cytosorbents Corporation ( NASDAQ:CTSO ) share price has dived 28% in the last...Rentabilidad de los accionistas
| CTSO | US Medical Equipment | Mercado US | |
|---|---|---|---|
| 7D | -5.6% | -1.9% | -2.0% |
| 1Y | -65.0% | -18.7% | 17.2% |
Rentabilidad vs. Industria: Los resultados de CTSO fueron inferiores a los de la industria US Medical Equipment, que obtuvo un rendimiento del -18.7% el año pasado.
Rentabilidad vs. Mercado: CTSO obtuvo unos resultados inferiores a los del mercado US, que fueron del 17.2% el año pasado.
Volatilidad de los precios
| CTSO volatility | |
|---|---|
| CTSO Average Weekly Movement | 12.9% |
| Medical Equipment Industry Average Movement | 8.4% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.2% |
Precio estable de las acciones: El precio de las acciones de CTSO ha sido volátil durante los últimos 3 meses en comparación con el mercado US.
Volatilidad a lo largo del tiempo: La volatilidad semanal de CTSO(13%) se ha mantenido estable durante el último año, pero sigue siendo superior al 75% de las acciones de US.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1997 | 129 | Phil Chan | www.cytosorbents.com |
Cytosorbents Corporation se dedica a la investigación, el desarrollo y la comercialización de dispositivos médicos con su plataforma tecnológica de purificación de la sangre en Estados Unidos, Alemania y a escala internacional. Su producto estrella, CytoSorb, es un cartucho de purificación extracorpórea de la sangre para reducir las tormentas de citoquinas en enfermedades críticas comunes, la bilirrubina en insuficiencia hepática, la mioglobina en traumatismos y enfermedades críticas, y los mediadores inflamatorios y anticoagulantes en aplicaciones de cirugía cardiaca, así como para eliminar fármacos antitrombóticos y mediadores inflamatorios en aplicaciones de cirugía cardiotorácica. La empresa también desarrolla el sistema de eliminación de antitrombóticos DrugSorb-ATR, un dispositivo en investigación para reducir la gravedad de las hemorragias perioperatorias en cirugía de alto riesgo debidas a fármacos anticoagulantes; ECOS-300CY para reducir las citocinas y otros mediadores inflamatorios cuando se utiliza en un sistema de perfusión de órganos ex vivo; VetResQ, un adsorbente de purificación sanguínea de amplio espectro para el tratamiento de shock séptico, síndrome de shock tóxico, enfermedades mediadas por toxinas, pancreatitis, traumatismos, insuficiencia hepática, golpes de calor y lesiones pulmonares en animales; y PuriFi, una bomba avanzada de hemoperfusión para terapias de purificación sanguínea.
Resumen de fundamentos de Cytosorbents Corporation
| Estadísticas fundamentales de CTSO | |
|---|---|
| Capitalización bursátil | US$23.20m |
| Beneficios(TTM) | -US$11.85m |
| Ingresos (TTM) | US$37.20m |
¿Está CTSO sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de CTSO | |
|---|---|
| Ingresos | US$37.20m |
| Coste de los ingresos | US$10.79m |
| Beneficio bruto | US$26.41m |
| Otros gastos | US$38.26m |
| Beneficios | -US$11.85m |
Últimos beneficios comunicados
Mar 31, 2026
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -0.19 |
| Margen bruto | 71.01% |
| Margen de beneficio neto | -31.85% |
| Ratio deuda/patrimonio | 773.0% |
¿Cómo se ha desempeñado CTSO a largo plazo?
Ver rendimiento histórico y comparativaAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/07/17 23:18 |
| Precio de las acciones al final del día | 2026/07/17 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Cytosorbents Corporation está cubierta por 5 analistas. 2 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Sean Lee | H.C. Wainwright & Co. |
| Anthony Petrone | Jefferies LLC |
| Danielle Antalffy | Leerink Partners LLC |